Zenjiro Maruyama

826 total citations
7 papers, 699 citations indexed

About

Zenjiro Maruyama is a scholar working on Molecular Biology, Oncology and Cancer Research. According to data from OpenAlex, Zenjiro Maruyama has authored 7 papers receiving a total of 699 indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Molecular Biology, 5 papers in Oncology and 2 papers in Cancer Research. Recurrent topics in Zenjiro Maruyama's work include Bone Metabolism and Diseases (5 papers), Bone health and treatments (3 papers) and Cancer-related Molecular Pathways (2 papers). Zenjiro Maruyama is often cited by papers focused on Bone Metabolism and Diseases (5 papers), Bone health and treatments (3 papers) and Cancer-related Molecular Pathways (2 papers). Zenjiro Maruyama collaborates with scholars based in Japan and United States. Zenjiro Maruyama's co-authors include Toshihisa Komori, Hiroshi Kawaguchi, Kozo Nakamura, Ung‐il Chung, Hirotaka Chikuda, Kazuto Hoshi, Takashi Shimoaka, Satoru Kamekura, Toshihiro Miyazaki and Takeshi Moriishi and has published in prestigious journals such as Journal of Biological Chemistry, PLoS ONE and Oncogene.

In The Last Decade

Zenjiro Maruyama

7 papers receiving 689 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Zenjiro Maruyama Japan 7 447 282 187 119 77 7 699
Bo Yan China 14 401 0.9× 215 0.8× 139 0.7× 106 0.9× 58 0.8× 20 831
Eriko Aoyama Japan 22 873 2.0× 224 0.8× 133 0.7× 149 1.3× 44 0.6× 48 1.2k
Leilei Zhong China 17 373 0.8× 409 1.5× 138 0.7× 145 1.2× 87 1.1× 36 875
Valerie A. Siclari United States 9 341 0.8× 102 0.4× 281 1.5× 120 1.0× 50 0.6× 10 658
Guochun Zhu United States 18 650 1.5× 168 0.6× 252 1.3× 195 1.6× 47 0.6× 25 882
Klaus Bobacz Austria 14 334 0.7× 547 1.9× 130 0.7× 96 0.8× 176 2.3× 30 915
Takashi Izawa Japan 16 366 0.8× 263 0.9× 153 0.8× 96 0.8× 49 0.6× 34 739
Hong-In Shin South Korea 15 446 1.0× 171 0.6× 147 0.8× 62 0.5× 23 0.3× 21 783
Takuo Juji Japan 12 539 1.2× 500 1.8× 382 2.0× 188 1.6× 81 1.1× 28 996
Yoshifumi Mori Japan 11 284 0.6× 331 1.2× 62 0.3× 124 1.0× 102 1.3× 15 676

Countries citing papers authored by Zenjiro Maruyama

Since Specialization
Citations

This map shows the geographic impact of Zenjiro Maruyama's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Zenjiro Maruyama with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Zenjiro Maruyama more than expected).

Fields of papers citing papers by Zenjiro Maruyama

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Zenjiro Maruyama. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Zenjiro Maruyama. The network helps show where Zenjiro Maruyama may publish in the future.

Co-authorship network of co-authors of Zenjiro Maruyama

This figure shows the co-authorship network connecting the top 25 collaborators of Zenjiro Maruyama. A scholar is included among the top collaborators of Zenjiro Maruyama based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Zenjiro Maruyama. Zenjiro Maruyama is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

7 of 7 papers shown
1.
Ito, Kosei, Zenjiro Maruyama, Akiko Sakai, et al.. (2013). Overexpression of Cdk6 and Ccnd1 in chondrocytes inhibited chondrocyte maturation and caused p53-dependent apoptosis without enhancing proliferation. Oncogene. 33(14). 1862–1871. 20 indexed citations
2.
Yoshida, Carolina A., Hisato Komori, Zenjiro Maruyama, et al.. (2012). SP7 Inhibits Osteoblast Differentiation at a Late Stage in Mice. PLoS ONE. 7(3). e32364–e32364. 78 indexed citations
3.
Moriishi, Takeshi, Zenjiro Maruyama, Ryo Fukuyama, et al.. (2011). Overexpression of Bcl2 in Osteoblasts Inhibits Osteoblast Differentiation and Induces Osteocyte Apoptosis. PLoS ONE. 6(11). e27487–e27487. 55 indexed citations
4.
Maruyama, Zenjiro, Carolina A. Yoshida, Tatsuya Furuichi, et al.. (2007). Runx2 determines bone maturity and turnover rate in postnatal bone development and is involved in bone loss in estrogen deficiency. Developmental Dynamics. 236(7). 1876–1890. 203 indexed citations
5.
Kamekura, Satoru, Yosuke Kawasaki, Kazuto Hoshi, et al.. (2006). Contribution of runt‐related transcription factor 2 to the pathogenesis of osteoarthritis in mice after induction of knee joint instability. Arthritis & Rheumatism. 54(8). 2462–2470. 263 indexed citations
6.
Ogasawara, Toru, Hirotaka Chikuda, Toshiyuki Ikeda, et al.. (2005). Inhibition of Cdk6 expression through p38 MAP kinase is involved in differentiation of mouse prechondrocyte ATDC5. Journal of Cellular Physiology. 204(3). 927–933. 21 indexed citations
7.
Shimoaka, Takashi, Satoru Kamekura, Hirotaka Chikuda, et al.. (2004). Impairment of Bone Healing by Insulin Receptor Substrate-1 Deficiency. Journal of Biological Chemistry. 279(15). 15314–15322. 59 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026